RECK Gene
Reversion Inducing Cysteine Rich Protein With Kazal Motifs
Gene Information Card
| Symbol | RECK |
|---|---|
| Full Name | Reversion Inducing Cysteine Rich Protein With Kazal Motifs |
| Gene Type | protein-coding |
| Chromosomal Location | 9p13.3 |
| NCBI Gene ID | 8434 ncbi.nlm.nih.gov/gene/8434 |
| Ensembl ID | ENSG00000107175 |
| UniProt ID | O95980 |
| OMIM ID | 605227 |
| HGNC ID | 9944 |
| Aliases | ST15, hRECK, MGC126518, MGC126520 |
Description
The RECK gene encodes a membrane-anchored glycoprotein that functions as a negative regulator of matrix metalloproteinases (MMPs), particularly MMP-2, MMP-9, and MT1-MMP. It is widely expressed in normal tissues but frequently downregulated in various cancers, contributing to tumor invasion and metastasis. RECK is considered a tumor suppressor gene.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal Cancer | Downregulation of RECK leads to increased MMP activity, promoting invasion and metastasis. | PMID: 15604238 |
| Breast Cancer | Reduced RECK expression correlates with poor prognosis and increased metastatic potential. | PMID: 16115910 |
| Lung Cancer | Epigenetic silencing of RECK via promoter methylation enhances tumor progression. | PMID: 17699744 |
| Gastric Cancer | Loss of RECK expression is associated with lymph node metastasis and advanced stage. | PMID: 17260019 |
| Hepatocellular Carcinoma | RECK downregulation promotes MMP-mediated extracellular matrix degradation and invasion. | PMID: 18626450 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Heart | 8.3 | Low |
| Liver | 15.7 | Medium |
| Lung | 18.2 | Medium |
| Kidney | 22.1 | Medium |
| Pancreas | 9.8 | Low |
| Spleen | 14.0 | Medium |
| Testis | 25.4 | High |
| Ovary | 11.3 | Medium |
| Colon | 16.9 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 20.5 | Cervical cancer cell line |
| A549 | 15.3 | Lung cancer cell line |
| MCF7 | 12.8 | Breast cancer cell line |
| HepG2 | 18.1 | Hepatocellular carcinoma cell line |
| HT-29 | 14.6 | Colorectal adenocarcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | Missense | <0.1% | Unknown |
| c.245C>T | Nonsense | <0.1% | Predicted loss of function |
| c.678_679insA | Frameshift | <0.1% | Predicted loss of function |
| c.1024G>A | Missense | <0.1% | Unknown |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations are predicted to cause loss of RECK function, reducing MMP inhibition and promoting invasive behavior.
Gain of Function (GOF)
No gain-of-function mutations have been reported for RECK.
Dominant Negative (DN)
No dominant-negative mutations have been described for RECK.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Matrix Metalloproteinase Inhibition
• Extracellular Matrix Remodeling
• Tumor Suppression via MMP Regulation
Protein Summary
The RECK protein is a 971-amino acid glycoprotein anchored to the plasma membrane via a C-terminal glycosylphosphatidylinositol (GPI) anchor. It contains multiple Kazal-like domains that inhibit matrix metalloproteinases (MMPs), including MMP-2, MMP-9, and MT1-MMP. By regulating MMP activity, RECK controls extracellular matrix remodeling, cell migration, and angiogenesis. Loss of RECK expression is a hallmark of many aggressive cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| RECK Knockout HEK293 Cell Line | EDJ-KQ3203 | Human | 8434 | Details Get a Quote |
| RECK Knockout A-549 Cell Line | EDJ-KQ24664 | Human | 8434 | Details Get a Quote |
| RECK Knockout HCT 116 Cell Line | EDJ-KQ24665 | Human | 8434 | Details Get a Quote |
| RECK Knockout HeLa Cell Line | EDJ-KQ24666 | Human | 8434 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
